Skip to content
10-Q

Quarterly Report

MapLight Therapeutics, Inc. MPLT

0001193125-26-224129

← back to feed
Filed
May 14, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted Q1 2026 · Mar 31, 2026 45.28M sh
Shares Diluted Q1 2026 · Mar 31, 2025 761.6K sh
Capex Q1 2026 · Mar 31, 2026 $24K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$51.18M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$25.55M
Short Term Investments Q1 2026 · Mar 31, 2026 $254.41M
Short Term Investments Q1 2026 · Dec 31, 2025 $258.37M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $55.71M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $46.73M
Stockholders Equity Q1 2026 · Mar 31, 2026 $399.83M
Stockholders Equity Q1 2026 · Dec 31, 2025 $458.37M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$215.83M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$193.63M
Current Liabilities Q1 2026 · Mar 31, 2026 $14.28M
Current Liabilities Q1 2026 · Dec 31, 2025 $16.23M
Total Liabilities Q1 2026 · Mar 31, 2026 $18.95M
Total Liabilities Q1 2026 · Dec 31, 2025 $21.14M
Current Assets Q1 2026 · Mar 31, 2026 $327.23M
Current Assets Q1 2026 · Dec 31, 2025 $324.67M
Total Assets Q1 2026 · Mar 31, 2026 $418.79M
Total Assets Q1 2026 · Dec 31, 2025 $479.51M
Eps Diluted Q1 2026 · Mar 31, 2026 −$1.34
Eps Diluted Q1 2026 · Mar 31, 2025 −$29.33
Eps Basic Q1 2026 · Mar 31, 2026 −$1.34
Eps Basic Q1 2026 · Mar 31, 2025 −$29.33
Sga Expense Q1 2026 · Mar 31, 2026 $10.82M
Sga Expense Q1 2026 · Mar 31, 2025 $3.76M
Rd Expense Q1 2026 · Mar 31, 2026 $53.68M
Rd Expense Q1 2026 · Mar 31, 2025 $19.79M
Net Income Q1 2026 · Mar 31, 2026 −$60.67M
Net Income Q1 2026 · Mar 31, 2025 −$22.34M
Operating Income Q1 2026 · Mar 31, 2026 −$64.5M
Operating Income Q1 2026 · Mar 31, 2025 −$23.54M